Stage IIA Breast Cancer
A breast cancer with T2 N0 M0 (tumor >2 cm but ≤5 cm, no regional lymph node involvement, no distant metastasis) is classified as Stage IIA. 1
TNM Classification Breakdown
According to the ESMO Clinical Practice Guidelines, the staging is determined by combining the T, N, and M descriptors:
- T2: Tumor >20 mm but ≤50 mm in greatest dimension 1
- N0: No regional lymph node metastases 1
- M0: No clinical or radiographic evidence of distant metastases 1
Stage Grouping
When these three components are combined (T2 + N0 + M0), this definitively places the cancer in Stage IIA. This staging applies to both clinical staging (based on physical examination and imaging) and pathological staging (based on surgical specimen examination).
Important Clinical Context
The T2 category itself can be subdivided:
- T2a: Tumors >20 mm to ≤40 mm
- T2b: Tumors >40 mm to ≤50 mm
However, both T2a and T2b with N0 M0 remain Stage IIA. The distinction between T2a and T2b may have prognostic implications—research suggests that larger tumors within the T2 category (particularly >40 mm) may have worse outcomes 2—but this does not change the overall stage grouping.
Prognostic Considerations
Stage IIA breast cancer represents early-stage disease with generally favorable prognosis when appropriately treated. Historical data shows that T2N0M0 patients have approximately 63-68% recurrence-free survival at 20 years without modern systemic therapy 3, 4. With contemporary treatment approaches including appropriate systemic therapy, outcomes have improved substantially, with 5-year relative survival rates exceeding 95% in recent cohorts 5.
The absence of lymph node involvement (N0) is a critical favorable prognostic factor, though tumor size within the T2 range (2-5 cm) still warrants consideration of adjuvant systemic therapy based on tumor biology, receptor status, and genomic profiling 6.